1. Publication
- Title: Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial
- Acronym: None assigned
- Year & Journal: American Journal of Gastroenterology, published November 21, 2025
- Citation: Verma N, Chakrabarti A, Shafiq N, Duseja A, et al. Am J Gastroenterol. 2025. NCT04157465
2. Context & Rationale
Background: Invasive fungal infections (IFI) in acute-on-chronic liver failure (ACLF) are associated with transplant delisting, high morbidity, and mortality. The optimal antifungal strategy — empirical (started at high-risk identification) vs diagnostic/biomarker-driven pre-emptive (started only on confirmation) — remained uncertain. Notably, prior ICU-population trials (EMPIRICUS) found no benefit from empirical antifungal therapy in non-liver-failure critically ill patients, making this a genuinely open, population-specific question.
Research Question/Hypothesis: In hospitalized ACLF patients with predefined risk factors for IFI, does empirical antifungal therapy at enrollment improve 28-day overall survival compared with diagnostic/biomarker-driven pre-emptive therapy?
3. Design & Methods
- Study Type: Parallel-group, pragmatic, randomized trial with blinded endpoint adjudication
- Setting & Centers: High-burden setting (India)
- Population: 216 hospitalized ACLF patients with predefined host/clinical IFI risk factors
- Intervention: Empirical antifungal therapy at enrollment, with biomarker/culture-guided stewardship
- Comparator: Diagnostic/biomarker-driven pre-emptive therapy (started on lab/radiological/mycological confirmation), same stewardship protocols
- Randomization: 1:1, 216 patients
- Blinding: Blinded endpoint adjudication
- Statistical Power & Follow-Up: Primary: 28-day overall survival. Secondary: in-hospital mortality, severity score changes, adverse events, cost-effectiveness. Heterogeneous treatment effects explored via causal tree analysis.
4. Key Results
216 patients randomized.
Outcome | Empirical Antifungal | Diagnostic/Pre-emptive | Effect Size | Notes |
28-day overall survival (primary) | 35% | 13% | Not fully reported in accessible text (HR cited but truncated) | Significant benefit with empirical therapy |
In-hospital mortality, severity scores, adverse events | Favorable trends reported | — | Not fully specified | Secondary outcomes support primary finding |
Note on data completeness: The exact hazard ratio and confidence interval for the primary outcome were truncated in the accessible source text; the 35% vs 13% survival figures and "significant" characterization are clearly reported.
5. Internal Validity Assessment
Randomized with blinded endpoint adjudication and standardized antifungal stewardship protocols applied in both arms (isolating the specific timing strategy, not overall stewardship quality). Overall: Moderate-to-strong — a meaningful, large absolute survival difference (35% vs 13%) in a population-specific, appropriately targeted trial; single-country design and truncated statistical detail in accessible sources are limitations for this summary.
6. External Validity Assessment
High-burden Indian ACLF population with predefined IFI risk factors — relevant to similar high-IFI-burden liver-failure settings; ACLF-specific results should not be extrapolated to general critically ill populations (where EMPIRICUS found no benefit).
7. Strengths & Limitations
Strengths: Blinded endpoint adjudication; standardized stewardship in both arms isolating the timing-strategy question; large absolute survival benefit; population-specific design addressing a genuine ACLF-specific gap distinct from general-ICU antifungal evidence.
Limitations: Single-country/high-burden-setting trial; exact primary-outcome statistics not fully accessible for this summary.
8. Interpretation & Practice Impact
Supports empirical (rather than diagnostic-driven pre-emptive) antifungal therapy specifically in ACLF patients with predefined IFI risk factors — a notable contrast to the general critically ill population (EMPIRICUS), where empirical antifungal therapy showed no survival benefit, highlighting that ACLF's severe immune dysfunction may create a genuinely different risk-benefit balance favoring earlier treatment.
9. Controversies & Subsequent Evidence
This result stands in notable contrast to the EMPIRICUS trial (JAMA 2016), which found no survival benefit from empirical antifungal therapy in general ICU patients with sepsis, Candida colonization, and multiorgan failure — an important population-specific distinction, since ACLF patients have a documented "sepsis-like immune paralysis" that may fundamentally alter the risk-benefit calculus for empirical vs diagnostic-driven approaches.
10. Summary & Executive Takeaway
Summary: This pragmatic RCT with blinded endpoint adjudication randomized 216 high-IFI-risk ACLF patients to empirical antifungal therapy at enrollment or diagnostic/biomarker-driven pre-emptive therapy. 28-day survival was substantially higher with empirical therapy (35% vs 13%), a statistically significant benefit.
Overall Takeaway: Empirical antifungal therapy significantly improves survival in high-IFI-risk ACLF patients — a population-specific finding that contrasts with general ICU antifungal evidence (EMPIRICUS), reflecting ACLF's unique immune-dysfunction profile and supporting earlier, risk-based (rather than strictly diagnostic-confirmed) antifungal initiation in this specific, high-mortality population.
11. Bibliography
- Timsit JF, Azoulay E, Schwebel C, et al; EMPIRICUS Trial Group. Empirical Micafungin Treatment and Survival Without IFI in Adults With ICU-Acquired Sepsis. JAMA. 2016;316(15):1555-1564.
- Verma N, et al. Invasive fungal infections amongst patients with ACLF at high risk for fungal infections. Liver Int. 2019.